B-intervention	0	11	Trastuzumab
O	12	17	after
O	18	26	adjuvant
O	27	39	chemotherapy
O	40	42	in
B-eligibility	43	47	HER2
I-eligibility	47	48	-
I-eligibility	48	56	positive
I-eligibility	57	63	breast
I-eligibility	64	70	cancer
O	70	71	.

O	72	83	Trastuzumab
O	83	84	,
O	85	86	a
O	87	98	recombinant
O	99	109	monoclonal
O	110	118	antibody
O	119	126	against
O	127	131	HER2
O	131	132	,
O	133	136	has
O	137	145	clinical
O	146	154	activity
O	155	157	in
O	158	166	advanced
O	167	173	breast
O	174	180	cancer
O	181	185	that
O	186	199	overexpresses
O	200	204	HER2
O	204	205	.

O	206	208	We
O	209	221	investigated
O	222	225	its
O	226	234	efficacy
O	235	238	and
O	239	245	safety
O	246	251	after
O	252	260	excision
O	261	263	of
O	264	269	early
O	269	270	-
O	270	275	stage
O	276	282	breast
O	283	289	cancer
O	290	293	and
O	294	304	completion
O	305	307	of
O	308	320	chemotherapy
O	320	321	.

O	322	326	This
O	327	340	international
O	340	341	,
O	342	353	multicenter
O	353	354	,
O	355	365	randomized
O	366	371	trial
O	372	380	compared
O	381	384	one
O	385	387	or
O	388	391	two
O	392	397	years
O	398	400	of
O	401	412	trastuzumab
O	413	418	given
O	419	424	every
O	425	430	three
O	431	436	weeks
O	437	441	with
O	442	453	observation
O	454	456	in
O	457	465	patients
O	466	470	with
O	471	475	HER2
O	475	476	-
O	476	484	positive
O	485	488	and
O	489	495	either
O	496	500	node
O	500	501	-
O	501	509	negative
O	510	512	or
O	513	517	node
O	517	518	-
O	518	526	positive
O	527	533	breast
O	534	540	cancer
O	541	544	who
O	545	548	had
O	549	558	completed
O	559	571	locoregional
O	572	579	therapy
O	580	583	and
O	584	586	at
O	587	592	least
O	593	597	four
O	598	604	cycles
O	605	607	of
O	608	619	neoadjuvant
O	620	622	or
O	623	631	adjuvant
O	632	644	chemotherapy
O	644	645	.

O	646	650	Data
O	651	655	were
O	656	665	available
O	666	669	for
B-total-participants	670	674	1694
O	675	680	women
O	681	689	randomly
O	690	698	assigned
O	699	701	to
O	702	705	two
O	706	711	years
O	712	714	of
O	715	724	treatment
O	725	729	with
O	730	741	trastuzumab
O	741	742	,
B-intervention-participants	743	747	1694
O	748	753	women
O	754	762	assigned
O	763	765	to
O	766	769	one
O	770	774	year
O	775	777	of
O	778	789	trastuzumab
O	789	790	,
O	791	794	and
B-control-participants	795	799	1693
O	800	805	women
O	806	814	assigned
O	815	817	to
B-control	818	829	observation
O	829	830	.

O	831	833	We
O	834	840	report
O	841	845	here
O	846	849	the
O	850	857	results
O	858	862	only
O	863	865	of
O	866	875	treatment
O	876	880	with
O	881	892	trastuzumab
O	893	896	for
O	897	900	one
O	901	905	year
O	906	908	or
O	909	920	observation
O	920	921	.

O	922	924	At
O	925	928	the
O	929	934	first
O	935	942	planned
O	943	950	interim
O	951	959	analysis
O	960	961	(
O	961	967	median
O	968	974	follow
O	974	975	-
O	975	977	up
O	978	980	of
O	981	984	one
O	985	989	year
O	989	990	)
O	990	991	,
O	992	995	347
B-outcome	996	1002	events
O	1003	1004	(
B-outcome	1004	1014	recurrence
I-outcome	1015	1017	of
I-outcome	1018	1024	breast
I-outcome	1025	1031	cancer
I-outcome	1031	1032	,
I-outcome	1033	1046	contralateral
I-outcome	1047	1053	breast
I-outcome	1054	1060	cancer
I-outcome	1060	1061	,
I-outcome	1062	1068	second
I-outcome	1069	1078	nonbreast
I-outcome	1079	1088	malignant
I-outcome	1089	1096	disease
I-outcome	1096	1097	,
I-outcome	1098	1100	or
I-outcome	1101	1106	death
O	1106	1107	)
O	1108	1112	were
O	1113	1121	observed
O	1121	1122	:
B-iv-bin-abs	1123	1126	127
O	1127	1133	events
O	1134	1136	in
O	1137	1140	the
O	1141	1152	trastuzumab
O	1153	1158	group
O	1159	1162	and
B-cv-bin-abs	1163	1166	220
O	1167	1169	in
O	1170	1173	the
O	1174	1185	observation
O	1186	1191	group
O	1191	1192	.

O	1193	1196	The
O	1197	1207	unadjusted
O	1208	1214	hazard
O	1215	1220	ratio
O	1221	1224	for
O	1225	1227	an
O	1228	1233	event
O	1234	1236	in
O	1237	1240	the
O	1241	1252	trastuzumab
O	1253	1258	group
O	1258	1259	,
O	1260	1262	as
O	1263	1271	compared
O	1272	1276	with
O	1277	1280	the
O	1281	1292	observation
O	1293	1298	group
O	1298	1299	,
O	1300	1303	was
O	1304	1305	0
O	1305	1306	.
O	1306	1308	54
O	1309	1310	(
O	1310	1312	95
O	1313	1320	percent
O	1321	1331	confidence
O	1332	1340	interval
O	1340	1341	,
O	1342	1343	0
O	1343	1344	.
O	1344	1346	43
O	1347	1349	to
O	1350	1351	0
O	1351	1352	.
O	1352	1354	67
O	1354	1355	;
O	1356	1357	P
O	1357	1358	<
O	1358	1359	0
O	1359	1360	.
O	1360	1364	0001
O	1365	1367	by
O	1368	1371	the
O	1372	1375	log
O	1375	1376	-
O	1376	1380	rank
O	1381	1385	test
O	1385	1386	,
O	1387	1395	crossing
O	1396	1399	the
O	1400	1407	interim
O	1408	1416	analysis
O	1417	1425	boundary
O	1425	1426	)
O	1426	1427	,
O	1428	1440	representing
O	1441	1443	an
O	1444	1452	absolute
O	1453	1460	benefit
O	1461	1463	in
O	1464	1469	terms
O	1470	1472	of
B-outcome	1473	1480	disease
I-outcome	1480	1481	-
I-outcome	1481	1485	free
I-outcome	1486	1494	survival
I-outcome	1495	1497	at
I-outcome	1498	1501	two
I-outcome	1502	1507	years
O	1508	1510	of
O	1511	1512	8
O	1512	1513	.
O	1513	1514	4
O	1515	1525	percentage
O	1526	1532	points
O	1532	1533	.

B-outcome	1534	1541	Overall
I-outcome	1542	1550	survival
O	1551	1553	in
O	1554	1557	the
O	1558	1561	two
O	1562	1568	groups
O	1569	1572	was
O	1573	1576	not
O	1577	1590	significantly
O	1591	1600	different
O	1601	1602	(
B-iv-bin-abs	1602	1604	29
B-outcome	1605	1611	deaths
O	1612	1616	with
O	1617	1628	trastuzumab
O	1629	1631	vs
O	1631	1632	.
B-cv-bin-abs	1633	1635	37
O	1636	1640	with
O	1641	1652	observation
O	1652	1653	)
O	1653	1654	.

B-outcome	1655	1661	Severe
I-outcome	1662	1676	cardiotoxicity
O	1677	1686	developed
O	1687	1689	in
B-iv-bin-percent	1690	1691	0
I-iv-bin-percent	1691	1692	.
I-iv-bin-percent	1692	1693	5
I-iv-bin-percent	1694	1701	percent
O	1702	1704	of
O	1705	1708	the
O	1709	1714	women
O	1715	1718	who
O	1719	1723	were
O	1724	1731	treated
O	1732	1736	with
O	1737	1748	trastuzumab
O	1748	1749	.

O	1750	1753	One
O	1754	1758	year
O	1759	1761	of
O	1762	1771	treatment
O	1772	1776	with
O	1777	1788	trastuzumab
O	1789	1794	after
O	1795	1803	adjuvant
O	1804	1816	chemotherapy
O	1817	1830	significantly
O	1831	1839	improves
O	1840	1847	disease
O	1847	1848	-
O	1848	1852	free
O	1853	1861	survival
O	1862	1867	among
O	1868	1873	women
O	1874	1878	with
O	1879	1883	HER2
O	1883	1884	-
O	1884	1892	positive
O	1893	1899	breast
O	1900	1906	cancer
O	1906	1907	.

O	1908	1909	(
O	1909	1923	ClinicalTrials
O	1923	1924	.
O	1925	1928	gov
O	1929	1935	number
O	1935	1936	,
O	1937	1948	NCT00045032
O	1948	1949	.
O	1949	1950	)
